Stares M, Doyle E, Chapple S, Raynes G, et al. Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 >/= 50 % progressing on first-line pembrolizumab. Lung Cancer 2024;189:107497.
PMID: 38295631